Earnings Call · Q1 FY2024·2024-05-09

Q1 24EPS +17.65%·Rev n/aQ4 23EPS -1.39%·Rev n/aQ3 23EPS +8.00%·Rev n/aQ2 23EPS -5.26%·Rev n/a⚠ consensus missing

Intellia Therapeutics, Inc. NTLA

Ian Karp — Senior Vice President, Investor Relations and Corporate Communications

John Leonard — President and Chief Executive Officer

David Lebwohl — Chief Medical Officer

Laura Sepp-Lorenzino — Chief Scientific Officer

Glenn Goddard — Chief Financial Officer

+8.1%1d on move date+7.5% vs SPY3d+10.5%5d+14.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NTLA calls or request research access.

More NTLA calls Browse calls Request research access